Skip to main content
Pure Biologics S.A. logo

Pure Biologics S.A. — Investor Relations & Filings

Ticker · PUR ISIN · PLPRBLG00010 LEI · 2594002TXS19AUYHIF82 WAR Manufacturing
Open in API
Filings indexed 515 across all filing types
Latest filing 2026-06-02 Governance Information
Country PL Poland
Listing WAR PUR

About Pure Biologics S.A.

https://purebiologics.com/

Pure Biologics S.A. is a biopharmaceutical company engaged in the discovery and development of novel biological drugs and non-systemic therapies. The company leverages its expertise in antibody and aptamer technologies to create innovative treatments. Its therapeutic portfolio is primarily focused on immuno-oncology. A key aspect of its strategy is the development of original, non-generic and non-biosimilar, biological drug candidates.

Recent filings

Filing Released Lang Actions
Sprawozdanie Rady Nadzorczej Pure Biologics S.A. za rok 2025
Governance Information Classification · 85% confidence The document is the Supervisory Board’s Report (“Sprawozdanie Rady Nadzorczej”) on its activities for the fiscal year 2025. It contains detailed evaluations of the company’s financial statements, management’s report, assessments of internal control systems, corporate governance practices, board composition and committees, and other governance matters. It is a substantive governance report rather than a simple announcement, earnings release, or proxy solicitation. This aligns with the Governance Information category (CGR).
2026-06-02 Polish
Treść projektów uchwał ZWZ Pure Biologics S.A. zwołanego na 29.06.2026
Proxy Solicitation & Information Statement Classification · 85% confidence The document consists entirely of "Projekty uchwał Zwyczajnego Walnego Zgromadzenia" – i.e., the draft resolutions and agenda items for the Ordinary General Meeting on June 29, 2026. These materials are provided to shareholders in advance to inform them of the items to be voted on and to solicit proxies. This matches the definition of a Proxy Solicitation & Information Statement, not an earnings release, board change notice, or actual AGM presentation. Therefore it should be classified as PSI.
2026-06-02 Polish
Treść ogłoszenia o zwołaniu ZWZ Pure Biologics S.A. na 29.06.2026
Proxy Solicitation & Information Statement Classification · 85% confidence The document is a formal notice (“Ogłoszenie … o zwołaniu Zwyczajnego Walnego Zgromadzenia”) of the company’s Annual General Meeting, detailing the date, agenda, shareholder participation and voting procedures. This is not the meeting minutes or voting results, nor actual financial statements, but is a proxy solicitation/information statement sent to shareholders to inform and request votes. The closest category is Proxy Solicitation & Information Statement (PSI).
2026-06-02 Polish
Informacja o zwołaniu Zwyczajnego Walnego Zgromadzenia Pure Biologics S.A. wraz z treścią projektów uchwał - Content (PL)
AGM Information Classification · 95% confidence The document is an official notice convening the Annual General Meeting (Zwyczajne Walne Zgromadzenie) of Pure Biologics S.A. on June 29, 2026, and it attaches agenda items, draft resolutions, and the Supervisory Board’s report—all materials for the AGM. This matches the definition of AGM Information (AGM-R).
2026-06-02 Polish
Śródroczne skrócone sprawozdanie finansowe Pure Biologics SA za okres 1.01-31.03.2026
Interim / Quarterly Report Classification · 96% confidence The document is a full interim condensed financial report (“Śródroczne Skrócone Sprawozdanie Finansowe”) for the period 01.01–31.03.2026. It includes complete financial statements (income statement, balance sheet, cash flows, statement of changes in equity) and explanatory notes, covering a period shorter than a full fiscal year. This matches the definition of an Interim / Quarterly Report (IR). Q1 2026
2026-05-29 Polish
Jednostkowy raport kwartalny Pure Biologics SA za 1Q 2026
Interim / Quarterly Report Classification · 93% confidence The document is titled “Jednostkowy raport kwartalny za okres 01.01.2026 – 31.03.2026 r.”, contains detailed interim results, selected financial data, a condensed financial statement, management commentary, and covers a quarter shorter than a full fiscal year. This matches the definition of an Interim/Quarterly Report (IR). Q1 2026
2026-05-29 Polish

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.